



COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. We have identified promising preclinical and clinical-stage antiviral therapeutics that target the replication process of influenza virus, norovirus, coronavirus and hepatitis C virus.

RECENT NEWS

Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Dec 18 2025, 8:00 AM EST

Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference

Dec 1 2025, 8:00 AM EST

Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Nov 14 2025, 8:00 AM EST

STOCK OVERVIEW

Symbol	COCP
Exchange	Nasdaq
Market Cap	13.51m
Last Price	\$0.98
52-Week Range	\$0.8588 - \$2.67

02/18/2026 09:00 PM EST

INVESTOR RELATIONS

Alliance Advisors IR
Jody Cain
T: 310-691-7100
Jcain@allianceadvisors.com

MANAGEMENT TEAM

Sam Lee, Ph.D.

Co-Chief Executive Officer and President

James J. Martin

Co-Chief Executive Officer and Chief Financial Officer

COCRYSTAL PHARMA, INC.

19805 North Creek Parkway
Bothell, WA 98011
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.